Arrowhead Pharmaceuticals, Inc. (ARWR)

Market Cap	9.12B +419.3%
Revenue (ttm)	1.09B +43,539.2%
Net Income	202.27M
EPS	1.48
Shares Out	140.03M
PE Ratio	44.16
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,670,522
Open	66.52
Previous Close	66.23
Day's Range	64.81 - 66.52
52-Week Range	10.37 - 76.76
Beta	1.27
Analysts	Strong Buy
Price Target	81.50 (+25.12%)
Earnings Date	May 11, 2026

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 1993
• Employees: 711
• Stock Exchange: NASDAQ
• Ticker Symbol: ARWR
• Website: https://arrowheadpharma.com

Financial Performance

In fiscal year 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024.

Analyst Summary

According to 10 analysts, the average rating for ARWR stock is "Strong Buy." The 12-month stock price target is $81.5, which is an increase of 25.12% from the latest price.

Price Target

$81.5

(25.12% upside)

Analyst Consensus: Strong Buy